The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Plasma concentrations of YKL-40 in chemo-naive patients with metastatic colorectal cancer treated with FLOX with or without cetuximab: Results from the NORDIC VII study.
Line Schmidt Tarpgaard
No relevant relationships to disclose
Tormod Kyrre Guren
No relevant relationships to disclose
Bengt Glimelius
Research Funding - Lilly; Merck Serono
Per Pfeiffer
Consultant or Advisory Role - Merck Serono (U); Roche (U)
Research Funding - Merck Serono; Roche
Elin Kure
No relevant relationships to disclose
Mette K. N. Yilmaz
No relevant relationships to disclose
Halfdan Sorbye
Consultant or Advisory Role - Merck Serono (U); Novartis
Honoraria - Bayer Schering Pharma; Novartis; Roche
Research Funding - Merck Serono
Nina Keldsen
No relevant relationships to disclose
Eva Skovlund
No relevant relationships to disclose
Julia S. Johansen
No relevant relationships to disclose
Kjell Magne Tveit
Research Funding - Merck Serono; Sanofi